Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Replimune開始進行RP2臨牀試驗，首批患者已在轉移性葡萄膜黑色素瘤和肝細胞癌中入組。
Advancing Its Oncolytic Immunotherapy Platform Following RP1 BLA Submission And Breakthrough Therapy Designation
在提交RP1生物製劑許可申請和突破性療法認定後，推進其溶瘤免疫療法平台
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。